These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 17989779)

  • 21. Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection.
    Martins TG; Trigo G; Fraga AG; Gama JB; Longatto-Filho A; Saraiva M; Silva MT; Castro AG; Pedrosa J
    PLoS Negl Trop Dis; 2012; 6(11):e1925. PubMed ID: 23209864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Former Buruli Ulcer Patients' Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management.
    Velink A; Woolley RJ; Phillips RO; Abass KM; van der Werf TS; Agumah E; de Zeeuw J; Klis S; Stienstra Y
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005261. PubMed ID: 28033343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer).
    Schütte D; Pluschke G
    Expert Opin Biol Ther; 2009 Feb; 9(2):187-200. PubMed ID: 19236249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Buruli ulcer. A disabling infection.
    Prescrire Int; 2010 Nov; 19(110):261-2. PubMed ID: 21284361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.
    Sarpong-Duah M; Frimpong M; Beissner M; Saar M; Laing K; Sarpong F; Loglo AD; Abass KM; Frempong M; Sarfo FS; Bretzel G; Wansbrough-Jones M; Phillips RO
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005695. PubMed ID: 28671942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histopathological changes and clinical responses of Buruli ulcer plaque lesions during chemotherapy: a role for surgical removal of necrotic tissue?
    Ruf MT; Sopoh GE; Brun LV; Dossou AD; Barogui YT; Johnson RC; Pluschke G
    PLoS Negl Trop Dis; 2011 Sep; 5(9):e1334. PubMed ID: 21980547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.
    Etuaful S; Carbonnelle B; Grosset J; Lucas S; Horsfield C; Phillips R; Evans M; Ofori-Adjei D; Klustse E; Owusu-Boateng J; Amedofu GK; Awuah P; Ampadu E; Amofah G; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3182-6. PubMed ID: 16048922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study.
    O'Brien DP; McDonald A; Callan P; Robson M; Friedman ND; Hughes A; Holten I; Walton A; Athan E
    PLoS Negl Trop Dis; 2012 Jan; 6(1):e1473. PubMed ID: 22272368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.
    Zhang T; Li SY; Converse PJ; Almeida DV; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2011 Jan; 55(1):56-61. PubMed ID: 21078940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Buruli ulcer disease in Republic of the Congo.
    Marion E; Obvala D; Babonneau J; Kempf M; Asiedu KB; Marsollier L
    Emerg Infect Dis; 2014 Jun; 20(6):1070-2. PubMed ID: 24857328
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.
    Sarfo FS; Phillips R; Asiedu K; Ampadu E; Bobi N; Adentwe E; Lartey A; Tetteh I; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3678-85. PubMed ID: 20566765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
    Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update.
    O'Brien DP; Jenkin G; Buntine J; Steffen CM; McDonald A; Horne S; Friedman ND; Athan E; Hughes A; Callan PP; Johnson PD
    Med J Aust; 2014 Mar; 200(5):267-70. PubMed ID: 24641151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans.
    Sarfo FS; Phillips RO; Ampadu E; Sarpong F; Adentwe E; Wansbrough-Jones M
    Clin Vaccine Immunol; 2009 Jan; 16(1):61-5. PubMed ID: 19005025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges Associated with Management of Buruli Ulcer/Human Immunodeficiency Virus Coinfection in a Treatment Center in Ghana: A Case Series Study.
    Tuffour J; Owusu-Mireku E; Ruf MT; Aboagye S; Kpeli G; Akuoku V; Pereko J; Paintsil A; Bonney K; Ampofo W; Pluschke G; Yeboah-Manu D
    Am J Trop Med Hyg; 2015 Aug; 93(2):216-23. PubMed ID: 26055745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Streptomycin injections for the treatment of Mycobacterium ulcerans (Buruli ulcer) in a rural health zone in the Democratic Republic of the Congo].
    Kibadi K
    Sante; 2007; 17(3):173-6. PubMed ID: 18180219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Buruli ulcer in West Africa: strategies for early detection and treatment in the antibiotic era.
    Webb BJ; Hauck FR; Houp E; Portaels F
    East Afr J Public Health; 2009 Aug; 6(2):144-7. PubMed ID: 20000019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Paradoxical reactions and responses during antibiotic treatment for Mycobacterium ulcerans infection (Buruli ulcer). Four cases from French Guiana].
    Sambourg E; Dufour J; Edouard S; Morris A; Mosnier E; Reynaud Y; Sainte-Marie D; Nacher M; Guégan JF; Couppié P
    Ann Dermatol Venereol; 2014; 141(6-7):413-8. PubMed ID: 24951139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mycobacterium ulcerans disease in the middle belt of Ghana: An eight-year review from six endemic districts.
    Adu EJ; Ampadu E
    Int J Mycobacteriol; 2015 Jun; 4(2):138-42. PubMed ID: 26972882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Local Cellular Immune Responses and Pathogenesis of Buruli Ulcer Lesions in the Experimental Mycobacterium Ulcerans Pig Infection Model.
    Bolz M; Ruggli N; Borel N; Pluschke G; Ruf MT
    PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004678. PubMed ID: 27128097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.